Boosting NAD+ blunts TLR4-induced type I IFN in control and systemic lupus erythematosus monocytes
BACKGROUND Fasting and NAD+-boosting compounds, including NAD+ precursor nicotinamide riboside (NR), confer antiinflammatory effects. However, the underlying mechanisms and therapeutic potential are incompletely defined.METHODS We explored the underlying biology in myeloid cells from healthy volunte...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical Investigation
2022-03-01
|
Series: | The Journal of Clinical Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1172/JCI139828 |